Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (NCT03734029)

🧪 Interventions in This Study

• Trastuzumab deruxtecan (DS-8201a) (DRUG)
• Capecitabine (DRUG)
• Eribulin (DRUG)
• Gemcitabine (DRUG)
• Paclitaxel (DRUG)
• Nab-paclitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (208 Sites)

Showing the first 25 of 208 sites.

• Ironwood Cancer & Research Centers - Chandler II — Chandler, Arizona
• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Cancer Treatment Centers of America at Western Regional Medical Center — Goodyear, Arizona
• UCLA School of Medicine — Los Angeles, California
• Stanford Cancer Institute — Palo Alto, California
• Cancer Care Associates Medical Group, Inc. TORI — Redondo Beach, California
• University of California at San Francisco (PARENT) — San Francisco, California
• Eastern Connecticut Hematology/Oncology Assoc. — Norwich, Connecticut
• Christiana Care Health Services, Inc. — Newark, Delaware
• Sylvester Comprehensive Cancer Center - Deerfield Beach — Boca Raton, Florida
• Florida Cancer Specialists (South Region) — Fort Myers, Florida
• Memorial Healthcare System MRH Cancer Center — Hollywood, Florida
• Orlando Health, Inc. — Orlando, Florida
• Moffitt Cancer Center -Tampa — Tampa, Florida
• Cancer Treatment Centers of America-Georgia — Newnan, Georgia
• University of Chicago Medical Center — Chicago, Illinois
• Cancer Treatment Centers of America — Zion, Illinois
• Cancer Center of Kansas — Wichita, Kansas
• Touro Infirmary — New Orleans, Louisiana
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Saint Luke's Hospital of Kansas City — Kansas City, Missouri
• Saint Barnabas Medical Center — Livingston, New Jersey
• New York University Medical Center — New York, New York
• Memorial Sloan Kettering Hospital — New York, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

• S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
• Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
• A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
• ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.